Literature DB >> 11118008

Mechanism by which metformin reduces glucose production in type 2 diabetes.

R S Hundal1, M Krssak, S Dufour, D Laurent, V Lebon, V Chandramouli, S E Inzucchi, W C Schumann, K F Petersen, B R Landau, G I Shulman.   

Abstract

To examine the mechanism by which metformin lowers endogenous glucose production in type 2 diabetic patients, we studied seven type 2 diabetic subjects, with fasting hyperglycemia (15.5 +/- 1.3 mmol/l), before and after 3 months of metformin treatment. Seven healthy subjects, matched for sex, age, and BMI, served as control subjects. Rates of net hepatic glycogenolysis, estimated by 13C nuclear magnetic resonance spectroscopy, were combined with estimates of contributions to glucose production of gluconeogenesis and glycogenolysis, measured by labeling of blood glucose by 2H from ingested 2H2O. Glucose production was measured using [6,6-2H2]glucose. The rate of glucose production was twice as high in the diabetic subjects as in control subjects (0.70 +/- 0.05 vs. 0.36 +/- 0.03 mmol x m(-2) min(-1), P < 0.0001). Metformin reduced that rate by 24% (to 0.53 +/- 0.03 mmol x m(-2) x min(-1), P = 0.0009) and fasting plasma glucose concentration by 30% (to 10.8 +/- 0.9 mmol/l, P = 0.0002). The rate of gluconeogenesis was three times higher in the diabetic subjects than in the control subjects (0.59 +/- 0.03 vs. 0.18 +/- 0.03 mmol x m(-2) min(-1) and metformin reduced that rate by 36% (to 0.38 +/- 0.03 mmol x m(-2) x min(-1), P = 0.01). By the 2H2O method, there was a twofold increase in rates of gluconeogenesis in diabetic subjects (0.42 +/- 0.04 mmol m(-2) x min(-1), which decreased by 33% after metformin treatment (0.28 +/- 0.03 mmol x m(-2) x min(-1), P = 0.0002). There was no glycogen cycling in the control subjects, but in the diabetic subjects, glycogen cycling contributed to 25% of glucose production and explains the differences between the two methods used. In conclusion, patients with poorly controlled type 2 diabetes have increased rates of endogenous glucose production, which can be attributed to increased rates of gluconeogenesis. Metformin lowered the rate of glucose production in these patients through a reduction in gluconeogenesis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11118008      PMCID: PMC2995498          DOI: 10.2337/diabetes.49.12.2063

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  38 in total

1.  Splanchnic and leg exchange of glucose, amino acids, and free fatty acids during exercise in diabetes mellitus.

Authors:  J Wahren; L Hagenfeldt; P Felig
Journal:  J Clin Invest       Date:  1975-06       Impact factor: 14.808

2.  Direct analysis of 18 O in glucose by mass spectrometry.

Authors:  R M Caprioli; W E Seifert
Journal:  Biochim Biophys Acta       Date:  1973-02-28

Review 3.  Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.

Authors:  R A DeFronzo
Journal:  Diabetes       Date:  1988-06       Impact factor: 9.461

4.  Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients.

Authors:  M S Wu; P Johnston; W H Sheu; C B Hollenbeck; C Y Jeng; I D Goldfine; Y D Chen; G M Reaven
Journal:  Diabetes Care       Date:  1990-01       Impact factor: 19.112

5.  Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy.

Authors:  G I Shulman; D L Rothman; T Jue; P Stein; R A DeFronzo; R G Shulman
Journal:  N Engl J Med       Date:  1990-01-25       Impact factor: 91.245

6.  Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.

Authors:  D G Maggs; T A Buchanan; C F Burant; G Cline; B Gumbiner; W A Hsueh; S Inzucchi; D Kelley; J Nolan; J M Olefsky; K S Polonsky; D Silver; T R Valiquett; G I Shulman
Journal:  Ann Intern Med       Date:  1998-02-01       Impact factor: 25.391

7.  Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

Authors:  S E Inzucchi; D G Maggs; G R Spollett; S L Page; F S Rife; V Walton; G I Shulman
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

8.  Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus.

Authors:  O G Kolterman; R S Gray; J Griffin; P Burstein; J Insel; J A Scarlett; J M Olefsky
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

9.  A microfluorometric method for the determination of free fatty acids in plasma.

Authors:  J Miles; R Glasscock; J Aikens; J Gerich; M Haymond
Journal:  J Lipid Res       Date:  1983-01       Impact factor: 5.922

10.  Relationship between hepatic glucose production and fasting plasma glucose concentration in patients with NIDDM.

Authors:  C Y Jeng; W H Sheu; M M Fuh; Y D Chen; G M Reaven
Journal:  Diabetes       Date:  1994-12       Impact factor: 9.461

View more
  297 in total

1.  Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes.

Authors:  Emilie Bahne; Emily W L Sun; Richard L Young; Morten Hansen; David P Sonne; Jakob S Hansen; Ulrich Rohde; Alice P Liou; Margaret L Jackson; Dayan de Fontgalland; Philippa Rabbitt; Paul Hollington; Luigi Sposato; Steven Due; David A Wattchow; Jens F Rehfeld; Jens J Holst; Damien J Keating; Tina Vilsbøll; Filip K Knop
Journal:  JCI Insight       Date:  2018-12-06

Review 2.  Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study.

Authors:  Vanita R Aroda; William C Knowler; Jill P Crandall; Leigh Perreault; Sharon L Edelstein; Susan L Jeffries; Mark E Molitch; Xavier Pi-Sunyer; Christine Darwin; Brandy M Heckman-Stoddard; Marinella Temprosa; Steven E Kahn; David M Nathan
Journal:  Diabetologia       Date:  2017-08-02       Impact factor: 10.122

3.  Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study.

Authors:  Elizabeth M Migoya; Jutta L Miller; Maria Gutierrez; Wei Zheng; Amy O Johnson-Levonas; Qi Liu; Catherine Z Matthews; John A Wagner; Keith M Gottesdiener
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

4.  Glucose and metformin modulate human first trimester trophoblast function: a model and potential therapy for diabetes-associated uteroplacental insufficiency.

Authors:  Christina S Han; Melissa A Herrin; Mary C Pitruzzello; Melissa J Mulla; Erika F Werner; Christian M Pettker; Clare A Flannery; Vikki M Abrahams
Journal:  Am J Reprod Immunol       Date:  2014-11-14       Impact factor: 3.886

5.  Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription.

Authors:  Yaomin Chen; Kun Zhou; Ruishan Wang; Yun Liu; Young-Don Kwak; Tao Ma; Robert C Thompson; Yongbo Zhao; Layton Smith; Laura Gasparini; Zhijun Luo; Huaxi Xu; Francesca-Fang Liao
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

Review 6.  Metabolic syndrome therapy: prevention of vascular injury by antidiabetic agents.

Authors:  Ligia J Dominguez; James R Sowers
Journal:  Curr Hypertens Rep       Date:  2005-04       Impact factor: 5.369

7.  Functional interplay between liver X receptor and AMP-activated protein kinase α inhibits atherosclerosis in apolipoprotein E-deficient mice - a new anti-atherogenic strategy.

Authors:  Chuanrui Ma; Wenwen Zhang; Xiaoxiao Yang; Ying Liu; Lipei Liu; Ke Feng; Xiaomeng Zhang; Shu Yang; Lei Sun; Miao Yu; Jie Yang; Xiaoju Li; Wenquan Hu; Robert Q Miao; Yan Zhu; Luyuan Li; Jihong Han; Yuanli Chen; Yajun Duan
Journal:  Br J Pharmacol       Date:  2018-03-23       Impact factor: 8.739

8.  Characterization of the heterozygous glucokinase knockout mouse as a translational disease model for glucose control in type 2 diabetes.

Authors:  D J Baker; A M Atkinson; G P Wilkinson; G J Coope; A D Charles; B Leighton
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

Review 9.  FoxO6 in glucose metabolism (FoxO6).

Authors:  Dae Hyun Kim; Ting Zhang; Sojin Lee; H Henry Dong
Journal:  J Diabetes       Date:  2013-05-28       Impact factor: 4.006

10.  Mechanistic Links between Obesity, Insulin, and Cancer.

Authors:  Rachel J Perry; Gerald I Shulman
Journal:  Trends Cancer       Date:  2020-01-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.